Clinical trial
SU5416 and Irinotecan in Treating Patients With Advanced Colorectal Cancer
NCT00005818 · National Cancer Institute (NCI), NIH · Completed
Key facts
| NCT number | NCT00005818 |
|---|---|
| Title | SU5416 and Irinotecan in Treating Patients With Advanced Colorectal Cancer |
| Official title | A Phase I/II Study of Escalating Doses of SU5416 (NSC 696819) in Combination With CPT-11 in Patients With Advanced Colorectal Carcinoma |
| Lead sponsor | National Cancer Institute (NCI), NIH |
| Status | Completed |
| Phase | Phase 1/Phase 2 |
| Study type | Interventional |
| Conditions | Adenocarcinoma of the Colon, Adenocarcinoma of the Rectum, Recurrent Colon Cancer, Recurrent Rectal Cancer, Stage III Colon Cancer, Stage III Rectal Cancer, Stage IV Colon Cancer, Stage IV Rectal Cancer |
| Intervention type | Drug, Other |
| Interventions | irinotecan hydrochloride, semaxanib, laboratory biomarker analysis |
| Enrollment | 68 |
| Start date | Mar 1, 2000 |
| Primary completion | Mar 1, 2003 |
| First posted | May 5, 2003 |
| Last update posted | Jan 23, 2013 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: